Insulin Gene in E. coli: Genetic Engineering, Not Gene Therapy

Inserting the human insulin gene into E. coli is genetic engineering (recombinant DNA technology), NOT gene therapy.

Key Distinctions

AspectGenetic Engineering (Insulin Production)Gene Therapy
TargetBacteria (E. coli) or yeastHuman patient's cells
PurposeManufacture therapeutic proteinTreat/prevent disease in patient
Genetic changeStable plasmid integration in microbeModify patient's somatic/germline DNA
ProductRecombinant insulin (purified)Therapeutic effect in vivo
RegulationBiologics manufacturing (FDA/EMA)Gene therapy trials (strict oversight)

Historical Context

  • 1978: First human insulin produced in E. coli (Genentech)
  • 1982: Humulin (recombinant human insulin) FDA-approved—first recombinant drug
  • Replaced animal-sourced insulin; identical to human, unlimited supply, fewer reactions

Current Production

  • E. coli and S. cerevisiae (yeast) both used commercially
  • Fermentation → purification → formulation
  • Strict GMP, no viable organisms in final product

This is industrial biotechnology—manufacturing a drug, not treating a patient's genes.

Diabetes - Related Articles